Phase II trial of vorinostat in advanced melanoma
Haas, N. B., Quirt, I., Hotte, S., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., vonMehren, M., Alpaugh, R. K., Zweibel, J., Oza, A.
Published in Investigational new drugs (01.06.2014)
Published in Investigational new drugs (01.06.2014)
Get full text
Journal Article
Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRa activation loop mutants in advanced gastrointestinal stromal tumor (GIST)
Heinrich, M, Jones, R, Schoffski, P, Bauer, S, vonMehren, M, Eskens, F, Cassier, P, Mir, O, Shi, H, Alvarez-Diez, T, Healy, ME, Wolf, B, George, S
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Published in European journal of cancer (1990) (01.12.2016)
Journal Article
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132
Wang, D., Zhang, Q., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C., Hoffman, J. P., Okuno, S. H., Kane, J. M., vonMehren, M., Eisenberg, B. L.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
WEINER, L. M, ALPAUGH, R. K, VON MEHREN, M
Published in Cancer Immunology, Immunotherapy (01.11.1997)
Published in Cancer Immunology, Immunotherapy (01.11.1997)
Get full text
Journal Article
Phase I trial of ilmofosine as a 24 hour infusion weekly
von Mehren, M, Giantonio, B J, McAleer, C, Schilder, R, McPhillips, J, O'Dwyer, P J
Published in Investigational new drugs (01.01.1995)
Published in Investigational new drugs (01.01.1995)
Get more information
Journal Article